Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management of EGFR mutation-positive non-small-cell lung cancer (NSCLC), with others in development. Although tumors are exquisitely sensiti...

Descripción completa

Detalles Bibliográficos
Autor principal: Hirsh, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784552/
https://www.ncbi.nlm.nih.gov/pubmed/29383041
http://dx.doi.org/10.1177/1758834017753338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784552/
https://www.ncbi.nlm.nih.gov/pubmed/29383041
http://dx.doi.org/10.1177/1758834017753338

Ejemplares similares